^
Association details:
| Biomarker: | FGFR2-OGA fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Excerpt:
...a 62 year-old white female found to have a left-sided intrahepatic mass with satellite lesions, with metastasis to regional lymph nodes...A biopsy of the liver mass revealed the presence of a poorly differentiated adenocarcinoma that was consistent with intrahepatic cholangiocarcinoma...She was found to have an FGFR2-MGEA5 fusion (Table 7 , Figure 2) and ponatinib monotherapy was pursued as salvage treatment....6 weeks after initiation of therapy she was noted to have anti-tumor activity...
DOI:
https://dx.doi.org/10.1371%2Fjournal.pgen.1004135
